The CRISPR/Cas9 system has shown great potential for precisely editing genomic DNA 27 sequences by introducing site-specific DNA cuts that are subsequently repaired by the cell. 28
and increased efficacy of a therapeutic unit (8-11). Recently, small molecule ligands (12) and 48 aptamers (13) have been coupled to the Cas9 protein or a Cas9 containing nanoparticle, 49 respectively, for receptor-mediated uptake into cells. The potential to specifically deliver Cas9 50 effects of gene editing specifically towards disease-causing cells. 52
53
The prospect of using Cas9 for gene knockdown/knockout is clearly understood and widely used, 54
however, applications such as homology directed repair (HDR) using donor DNA templates are 55 still in development in an in vivo setting. Having proved to be a powerful screening tool for 56 identifying gene essentiality, Cas9 may be used to overcome chemotherapy resistance (14) and 57 HDR precision would broaden the scope of this application. An ideal Cas9/chemotherapeutic 58 combination would involve targeted delivery through an overexpressed receptor on cancer cells 59 followed by knockout or correction of an oncogene, thereby maintaining or enhancing sensitivity 60 to a small molecule chemotherapeutic. We hypothesize that Cas9 delivered via receptor-mediated transfection can be targeted to BRCA2 75 creating a synthetic dose lethality of Cisplatin without additional transfection agents. However, 76 biodistribution, thereby reducing efficacy, tumour penetration and retention (21, 22). Thus, we 78 chose to use a nanobody (Nb) receptor-mediated transfection system, which maintains target 79 specificity with the added benefit of its smaller size (15 kDa), which does not substantially increase 80 the Cas9 hydrodynamic radius. For our study, we selected two low-EGFR expressing cell lines 81 (A549 and 3T3) rather than A431 (high EGFR expression) as a stringent challenge to the process 82 of receptor mediated transfection (23). Binding of EGFR targeted nanobodies to 3T3 are 83 equivalent to HeLa and A549 cells (24). In this short report, we tested the concept of receptor-84 mediated transfection of Cas9-Nb complexes leading to a synthetic Cisplatin dose lethality. 85
86

Results: 87
Nanobodies can be conjugated to Cas9 via NHS/EDC chemistry 88
To create a Cas9-Nb fusion, we applied amide coupling via NHS/EDC as the simplest method of 89 conjugation. In brief, Nb carboxylic acids were activated by EDC to form the o-acylisourea 90 intermediate that reacts with N-hydroxysulfosuccinimide (Fig. 1A) . Sulfo-succinimide forms a 91 stable reactive group in the aqueous phase. Lastly, adjustment of pH to greater than 7. Nb, respectively, in A549. Interestingly, a small non-specific dose response was also observed 124 for unconjugated Cas9-6Cys and Cas9MAV, though overall transfection level was low in 125 comparison to nanobody mediated transfection. 126
To explore the potential for synthetic dose lethality of Cisplatin, we pursued a BRCA2 knockout 130 in A549 cells to enhance the dose response to the drug (Fig. 3) . The RNP tested was Cas9-6Cys-131
Nb complexed to an sgRNA targeting BRCA2. Co-administration of Cas9-6Cys-Nb RNP and 132
Cisplatin was evaluated at a fixed protein concentration (8.3 pmol per well) and varying 133 concentrations of Cisplatin (0.2 -8 µM Cisplatin). Gene editing is most likely to demonstrate its 134 effect on cell viability post 48 hrs. This was validated at the 24 hr time point where Cisplatin-only 135
and RNP treated cells were indistinguishable (Fig. 3A) . 136 137 Co-administration of RNP and Cisplatin dosage over 72 hrs exposure resulted in the most notable 138 improvement in Cisplatin sensitivity, however, similar significant trends were also observed after 139 only 48 hrs. We know from previous work that 48-72 hrs incubation is sufficient to establish the 140 desired gene edit in a substantial population of cells. Furthermore, Cisplatin-induced apoptosis 141 and cell cycle arrest happens within 8-11 hrs of treatment (26), which is also evident from our 142 results at 24 hrs. 
Nanobody Expression and Purification 207
The 7D12 nanobody was expressed in BL21 (DE3) cells, induced with 0.5mM IPTG at OD600 = 208 0.9 and grown ON at 18°C. Cells were either subjected to complete cell lysis by sonication and 209 cleared by centrifugation, or partial lysis to obtain the protein from the periplasmic space, both 210 with similar low yields of 1mg/2L culture. The 7D12 Nb was subjected to Ni affinity 211 chromatography in buffer A (50 mM Tris pH8, 500 mL NaCl, 5% glycerol, 1 mM PMSF, 20 mM 212 imidazole) and eluted with 500 mM imidazole before being purified by gel filtration in 20 mM 213 HEPES pH 7.5, 150 mM NaCl. 
